pegaptanib sodium (Macugen)
pegaptanib sodium (Macugen) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
4 of 4 finished
0.0%
0 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
Clinical Trials (5)
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5